SAC Capital Advisors’s Myriad Genetics MYGN Stock Holding History

SAC Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-70,402	Closed	-$2.41M	–	673
2014 Q1	$2.41M	Buy	70,402 +29,488	+72%	+$914K	0.01%	723
2013 Q4	$858K	Sell	40,914 -206,169	-83%	-$5.21M	0.01%	971
2013 Q3	$5.81M	Buy	247,083 +225,771	+1,059%	+$6.41M	0.03%	481
2013 Q2	$573K	Buy	+21,312	New	+$618K	﹤0.01%	1062

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

SAC Capital Advisors's MYGN Position: Q2 2014 in Review

SAC Capital Advisors sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 70,402 shares — an estimated $2.41M sold.

SAC Capital Advisors first reported a position in MYGN in Q2 2013 and held it in 4 quarters. The position peaked at $5.81M in Q3 2013. 283 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

SAC Capital Advisors reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 70,402 Myriad Genetics shares in Q2 2014, an estimated $2.41M.
SAC Capital Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Myriad Genetics position peaked at $5.81M in Q3 2013.
283 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.